Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry
Open Access
- 11 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 171 (6), 911-919
- https://doi.org/10.1007/s00431-011-1644-x
Abstract
Our objective was to assess how the diagnosis and treatment of mucopolysaccharidosis I (MPS I) have changed over time. We used data from 891 patients in the MPS I Registry, an international observational database, to analyze ages at symptom onset, diagnosis, treatment initiation, and treatment allocation (hematopoietic stem cell transplantation, enzyme replacement therapy with laronidase, both, or neither) over time for all disease phenotypes (Hurler, Hurler–Scheie, and Scheie syndromes). The interval between diagnosis and treatment has become shorter since laronidase became available in 2003 (gap during 2006–2009: Hurler—0.2 year, Hurler–Scheie—0.5 year, Scheie—1.4 years). However, the age at diagnosis has not decreased for any MPS I phenotype over time, and the interval between symptom onset and treatment initiation remains substantial for both Hurler–Scheie and Scheie patients (gap during 2006–2009, 2.42 and 6.71 years, respectively). Among transplanted patients, an increasing proportion received hematopoietic stem cells from cord blood (34 out of 64 patients by 2009) and was also treated with laronidase (42 out of 45 patients by 2009). Conclusions: Despite the availability of laronidase since 2003, the diagnosis of MPS I is still substantially delayed for patients with Hurler–Scheie and Scheie phenotypes, which can lead to a sub-optimal treatment outcome. Increased awareness of MPS I signs and symptoms by primary care providers and pediatric subspecialists is crucial to initiate early treatment and to improve the quality of life of MPS I patients.Keywords
This publication has 34 references indexed in Scilit:
- Clinical manifestations and treatment of mucopolysaccharidosis type I patients in Latin America as compared with the rest of the worldJournal of Inherited Metabolic Disease, 2011
- Replacing the Enzyme α- l -Iduronidase at Birth Ameliorates Symptoms in the Brain and Periphery of Dogs with Mucopolysaccharidosis Type IScience Translational Medicine, 2010
- Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type IMolecular Genetics and Metabolism, 2010
- Childhood onset of Scheie syndrome, the attenuated form of mucopolysaccharidosis IJournal of Inherited Metabolic Disease, 2010
- Transplant Outcomes in MucopolysaccharidosesSeminars in Hematology, 2010
- Use of Enzyme Replacement Therapy (Laronidase) before Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis I: Experience in 18 PatientsThe Journal of Pediatrics, 2009
- The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UKOrphanet Journal of Rare Diseases, 2008
- Successful treatment of severe heart failure in an infant with Hurler syndromeJournal of Inherited Metabolic Disease, 2007
- Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failureBone Marrow Transplantation, 2007
- Haematopoietic cell transplantation (HCT) in combination with enzyme replacement therapy (ERT) in patients with Hurler syndromeBone Marrow Transplantation, 2006